Ryan Martins

Analysts Jim Birchenough, and Ryan Martins at Barclays Capital (ADR) (NYSE: BCS) have maintained a 1-Overweight rating for Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) on the back of a better-than-expected deal with AstraZeneca plc (ADR) (NYSE: AZN). According to analysts, the deal is one of the...

Following presentation of Phase I data for pan Bcr-Abl inhibitor -534 in advanced hematological cancers at ASH, Barclays has reiterated its Overweight rating for ARIAD Pharmaceuticals (NASDAQ: ARIA). Data presented in heavily pretreated CML pts including pts with the T315I mutation were impressive...